Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Fineline Cube Jan 16, 2026
Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Fineline Cube Jan 16, 2026
Company Deals

WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs

Fineline Cube Jan 24, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001

Fineline Cube Jan 24, 2024

Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a...

Company Deals

Shanghai Pharmaceutical and Sino Biopharmaceutical Form Strategic Partnership for Pharmaceutical Services

Fineline Cube Jan 24, 2024

Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607), a leading pharmaceutical company based in...

Company

J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth

Fineline Cube Jan 24, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for...

Company Medical Device

Establishment Labs Launches Motiva Breast Implants in China

Fineline Cube Jan 23, 2024

Establishment Labs Holdings Inc., (NASDAQ: ESTA), a US-based medical technology company specializing in women’s health,...

Company

Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services

Fineline Cube Jan 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to...

Company Medical Device

Zylox-Tonbridge Medical Technology Secures NMPA Nod for Innovative Iliac Vein Stent System

Fineline Cube Jan 23, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Drug

Eisai’s Uric Acid Excretion Drug Urece Accepted for Review in China

Fineline Cube Jan 23, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that it...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial

Fineline Cube Jan 23, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that...

Company Medical Device

Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China

Fineline Cube Jan 23, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry,...

Company Medical Device

Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device

Fineline Cube Jan 23, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease...

Company

LifeShield Medical Launches China HQ and Advanced Heart System Factory in Suzhou

Fineline Cube Jan 23, 2024

LifeShield Medical, a leading Sino-German multinational medical device company, has announced the official operation of...

Company Deals Digital Policy / Regulatory

Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative

Fineline Cube Jan 23, 2024

The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd,...

Company Deals

Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment

Fineline Cube Jan 23, 2024

Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab),...

Company Drug

HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jan 23, 2024

China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...

Policy / Regulatory

Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan

Fineline Cube Jan 23, 2024

The General Office of the CPC Central Committee and State Council has released the “Implementation...

Company Drug

AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment

Fineline Cube Jan 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...

Company Drug

Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Jan 23, 2024

Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...

Policy / Regulatory

NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions

Fineline Cube Jan 23, 2024

The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...

Company Deals

Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine

Fineline Cube Jan 23, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...

Posts pagination

1 … 355 356 357 … 610

Recent updates

  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
  • Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance
  • Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies
  • J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions
  • Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.